Background: Non small cell carcinomas of lung, notably adenocarcinoma is associated with genetic mutations in EGFR
(chromosome 7) , ALK (chromosome 2), ROS1(chromosome 6) . The patients harbouring these mutations are greatly
benefited from tyrosine kinase inhibitor targeted chemotherapy. The prevalence of these mutations in central kerala has
not been studied and documented.
Aim: This study aims to analyse the frequency of different mutations in lung adenocarcinomas presenting to a oncology
centre in kerala.
Study Design: Descriptive study.
Materials And Methods: The study spanned over a period of two years from 2019-2021. A total of 169 consecutive lung
adenocarcinomas were studied.
PCR for EGFR was done in 89 cases and were tested for the common mutations. ALK1 IHC using ALK-D5F3 clone and ROS
with ROS-D4D6 clones were done in 40 cases.
Results: EGFR mutation was present in 15 cases (17.44%). The most common age range was 40-60yrs. Two most
common patterns were solid and acinar. ALK and ROS 1 mutation was found in 3 cases (7.5%) and 2 cases ( 5%)
respectively. 4 cases (16.66%) of EGFR mutant lung adenocarcinoma patients had metastasis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.